Methylene Blue — Safety, Research, Risks & Legal Status

Not medical advice. Methylene Blue is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	methylthioninium chloride, basic blue 9, CI 52015
Category	Research Chemical
fda_approved	FDA-approved treatment for methemoglobinemia since early 1900s
mitochondrial_effects	Electron-transport-chain electron carrier that supports ATP production
weak_maoi	At higher doses functions as weak monoamine oxidase inhibitor
US legal status	Methylene blue is FDA-approved as a treatment for methemoglobinemia. It is also available as a dietary supplement and research chemical. Use for non-approved indications (cognitive enhancement, mitochondrial support) is off-label and not officially endorsed by regulatory agencies.

What is Methylene Blue?

Methylene blue is a synthetic redox-active dye that has been used medically for over a century. It functions as an antioxidant, electron carrier in mitochondrial electron transport, and monoamine oxidase inhibitor at higher doses.

How it works

Mitochondrial electron-transport chain electron carrier that supports ATP production and reduces oxidative stress. At higher doses, weak monoamine oxidase inhibition increases serotonin and dopamine levels.

Background & history

Synthesized in 1876 and used medically for over a century. FDA-approved for methemoglobinemia treatment. Rediscovered in neuroscience research for potential neuroprotective and cognitive effects; now available as dietary supplement and research chemical.

What the research says

Animal and small human studies suggest potential neuroprotective, antioxidant, and cognitive-enhancing effects via mitochondrial support. Research is preliminary; robust controlled human trials are lacking. Some studies report improvements in memory and cognition, but effect sizes are modest. Mechanisms in humans are not fully elucidated.

Reported effects

Studied for potential antioxidant and mitochondrial-support properties
Reported improvements in memory and cognitive function in small studies
Preclinical research suggests potential neuroprotective effects
Theoretical potential for supporting ATP production via electron transport
Studied as a potential adjunctive agent for neurodegenerative conditions (limited evidence)

Dosing & administration (informational)

Harm-reduction information only: pharmaceutical use for methemoglobinemia is well-established. Cognitive-enhancement use is off-label; user reports suggest wide dose variation without validated protocols.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Generally well-tolerated at low doses; long-term safety data are limited
At high doses, methylene blue acts as a monoamine oxidase inhibitor, increasing serotonin levels and risking serotonin syndrome when combined with SSRIs or other serotonergics
Can cause blue discoloration of urine and skin; benign but cosmetically notable
Rare reports of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency
Quality of research-chemical and supplement sources is variable

Drug & supplement interactions

SSRIs, SNRIs, and other serotonergics (serotonin syndrome risk at higher methylene-blue doses)
Monoamine oxidase inhibitors (potential for severe serotonin elevation)
Medications relying on hepatic metabolism (potential for drug-drug interactions via CYP450 effects)

Who should avoid it

Concurrent SSRIs or serotonergic agents (serotonin syndrome risk at higher doses)
Monoamine oxidase inhibitors (contraindicated due to serotonin elevation)
High-dose use (weak MAOI effects and unknown toxicity)
Use in individuals with G6PD deficiency (hemolytic anemia risk)

How it is commonly combined

Combining with serotonergic agents (SSRIs, serotonin agonists) increases serotonin-syndrome risk substantially at higher methylene-blue doses.

Legal & regulatory. Methylene blue is FDA-approved as a treatment for methemoglobinemia. It is also available as a dietary supplement and research chemical. Use for non-approved indications (cognitive enhancement, mitochondrial support) is off-label and not officially endorsed by regulatory agencies.

Quality & harm reduction

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is methylene blue safe for cognitive enhancement?

Methylene blue is FDA-approved for methemoglobinemia treatment. Cognitive enhancement use is off-label and not officially supported. Limited human evidence suggests modest benefits; long-term safety is unknown.

Can methylene blue cause serotonin syndrome?

Yes, at higher doses methylene blue acts as a weak MAOI and can increase serotonin levels. Concurrent use with SSRIs, SNRIs, or other serotonergic agents increases serotonin-syndrome risk.

Why does methylene blue turn urine blue?

Methylene blue is a dye and is excreted unchanged in urine. The blue discoloration is harmless but can be cosmetically concerning.

How much research exists on methylene blue and cognition?

Animal studies and small human trials suggest modest cognitive benefits, but robust, large-scale clinical trials are lacking. Evidence is preliminary and effect sizes are small.

Is pharmaceutical-grade methylene blue better than supplements?

Pharmaceutical-grade is more reliable for purity and potency. Supplements may have variable alkaloid content and contaminant risk; standardized extracts or pharmaceutical sources are preferable.

References & further reading

F
D
A
m
e
t
h
e
m
o
g
l
o
b
i
n
e
m
i
a
t
r
e
a
t
m
e
n
t
l
i
t
e
r
a
t
u
r
e
;
a
n
i
m
a
l
n
e
u
r
o
p
r
o
t
e
c
t
i
o
n
a
n
d
m
i
t
o
c
h
o
n
d
r
i
a
l
-
s
u
p
p
o
r
t
s
t
u
d
i
e
s
;
s
m
a
l
l
h
u
m
a
n
c
o
g
n
i
t
i
v
e
-
e
n
h
a
n
c
e
m
e
n
t
t
r
i
a
l
s
;
p
h
a
r
m
a
c
o
l
o
g
y
o
f
r
e
d
o
x
-
a
c
t
i
v
e
c
o
m
p
o
u
n
d
s
.